Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ENSC vs IMMX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IMMX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–3 Matrix Metrics)

IMMX Overall Winner 6-Pillar Tally: ENSC 2 – 3 IMMX (1 Tie) Matrix Metrics: ENSC 3 – 7 IMMX

As of Nov 20, 2026, Immix Biopharma, Inc. (IMMX) is the stronger overall head-to-head candidate over Ensysce Biosciences, Inc. (ENSC) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ENSC carries a Unified Composite Score of 53.4/100 (HOLD) at $0.36 (0.8x Forward P/E, -281.3% operating margin), whereas IMMX carries 50.6/100 (HOLD) at $6.96 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While ENSC currently prints a higher short-term Unified Composite Score (53.4/100 HOLD vs. IMMX 50.6/100 HOLD), IMMX captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -281.3% operating margin) and revenue trajectory (+0.0% vs. -15.1% YoY).
  • Technical & Structure Timing Caution: ENSC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.7); meanwhile IMMX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ENSC vs IMMX
ENSC NASDAQ
Ensysce Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$0.36
-0.17% 1D
Market Cap $7.0M
TTM Revenue $4.5M
Forward P/E 0.8x
Beta / 30D Vol 0.98β · 79% Vol
Unified Composite Score
53.4 / 100 HOLD
Tech 50.0 Fund 62.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.4%), weak momentum, RSI 40
RSI-14: 39.7 · SMA20: $0.39 · SMA50: $0.44
IMMX NASDAQ Head-to-Head Winner
Immix Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$6.96
-1.14% 1D
Market Cap $590.0M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.65β · 76% Vol
Unified Composite Score
50.6 / 100 HOLD
Tech 38.0 Fund 64.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -19.1%), weak momentum, RSI 36
RSI-14: 35.7 · SMA20: $7.77 · SMA50: $9.25

6-Pillar Scorecard Institutional Category Breakdown (ENSC 2 – 3 IMMX)

Columns: Metric · ENSC · IMMX
1. Valuation Multiples ENSC
Forward P/E 0.8x N/M
Trailing P/E 0.8x N/M
PEG Ratio N/M N/M
EV / Revenue 1.4x N/M
2. Growth & Scale IMMX
Revenue Growth (YoY) -15.1% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $4.5M N/A
Market Cap $7.0M $590.0M
3. Profitability & Quality IMMX
Gross Margin N/A N/A
Operating Margin -281.3% 0.0%
Net Profit Margin -280.5% 0.0%
Return on Equity (ROE) -1295.1% -27.0%
4. Balance Sheet & Cash Flow IMMX
Cash Generation (TTM) -$9.7M -$39M
Cash Flow Margin N/A N/A
Net Cash / Leverage -$499,633 Net Debt $224M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ENSC
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 164.9% (30th %ile)
Put/Call OI Skew N/A 0.05x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ENSC (3) vs IMMX (7)
Institutional Metric ENSC IMMX Criterion Row Edge
Market Capitalization
Scale
$7.0M $590.0M Larger Scale IMMX
Trailing P/E Ratio
Valuation
0.8x N/M Lower Multiple ENSC
Forward P/E Ratio
Valuation
0.8x N/M Lower Multiple ENSC
Revenue Growth (YoY)
Growth
-15.1% +0.0% Higher Growth IMMX
Operating Margin (TTM)
Profitability
-281.3% 0.0% Higher Margin IMMX
Net Profit Margin
Profitability
-280.5% 0.0% Higher Margin IMMX
Return on Equity (ROE)
Capital Efficiency
-1295.1% -27.0% Higher ROE IMMX
52-Week Range Position
Momentum
8% ($0–$2) 28% ($4–$15) Stronger Trend IMMX
Beta / 30D Volatility
Risk Regime
0.98β · 79% Vol 1.65β · 76% Vol Lower Realized Risk IMMX
Unified Institutional Score
Composite Signal
53.4 / 100 (HOLD) 50.6 / 100 (HOLD) Higher Composite ENSC
Trailing 12M Revenue (USD)
Operating Scale
$4.5M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.7M (-$499,633 Net Debt) -$39M ($224M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IMMX +12.9 pp
ENSC: -29.55% · IMMX: -16.65%
3M Horizon ENSC +48.58 pp
ENSC: -0.28% · IMMX: -48.86%
6M Horizon ENSC +33.72 pp
ENSC: +12.99% · IMMX: -20.73%
1Y Horizon IMMX +144.87 pp
ENSC: -80.33% · IMMX: +64.54%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ENSC vs IMMX. Trailing 12-month operating profitability (ENSC -281.3% vs IMMX 0.0%) and valuation multiples (ENSC 0.8x vs IMMX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ENSC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.5M
Gross MarginN/A
Op. Margin-281.3%
ROE / Fwd P/E-1295.1% · 0.8x
IMMX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-27.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ENSC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ENSC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IMMX BREAKDOWN
62d in phase · OBV DISTRIBUTION
Current IV 164.9%
IV Percentile 30th %ile
Put/Call OI Skew 0.05x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact IMMX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ENSC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.0M market capitalization and -281.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IMMX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $590.0M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ENSC vs IMMX Key Questions & Quantitative Answers

As of Nov 20, 2026, Immix Biopharma, Inc. (IMMX) is the stronger overall head-to-head candidate over Ensysce Biosciences, Inc. (ENSC) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ENSC carries a Unified Composite Score of 53.4/100 (HOLD) at $0.36 (0.8x Forward P/E, -281.3% operating margin), whereas IMMX carries 50.6/100 (HOLD) at $6.96 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ENSC currently prints a higher short-term Unified Composite Score (53.4/100 HOLD vs. IMMX 50.6/100 HOLD), IMMX captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -281.3% operating margin) and revenue trajectory (+0.0% vs. -15.1% YoY). Technical & Structure Timing Caution: ENSC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.7); meanwhile IMMX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IMMX leads the Growth & Scale pillar: ENSC posts -15.1% YoY revenue growth and +0.0% YoY earnings growth on $4.5M TTM revenue (N/A gross margin, -281.3% operating margin), compared with IMMX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ENSC generates $4.5M in USD-normalized revenue versus N/A for IMMX. In operating R&D and SG&A reinvestment, ENSC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IMMX.

ENSC screens cheaper on headline valuation multiples. ENSC trades at 0.8x Forward P/E, 0.8x Trailing P/E, N/M PEG, and 1.4x EV/Revenue (unreported FCF margin), whereas IMMX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENSC (-1295.1% ROE) versus IMMX (-27.0% ROE) capital efficiency.

In options market volatility and institutional positioning, ENSC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.98β · 79% Vol realized risk). By comparison, IMMX carries 164.9% implied volatility (30th %ile, Balanced (25th–60th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.65β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.